Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03911973
Title Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Kari Wisinski
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Gedatolisib + Talazoparib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.